Gurnari Carmelo, Robin Marie, Adès Lionel, Aljurf Mahmoud, Almeida Antonio, Duarte Fernando Barroso, Bernard Elsa, Cutler Corey, Della Porta Matteo Giovanni, De Witte Theo, DeZern Amy, Drozd-Sokolowska Joanna, Duncavage Eric, Fenaux Pierre, Gagelmann Nico, Garcia-Manero Guillermo, Haferlach Claudia, Haferlach Torsten, Hasserjian Robert, Hellström-Lindberg Eva, Jacoby Meagan, Kulasekararaj Austin, Lindsley R Coleman, Maciejewski Jaroslaw P, Makishima Hideki, Malcovati Luca, Mittelman Moshe, Myhre Anders E, Ogawa Seishi, Onida Francesco, Papaemmanuil Elli, Passweg Jakob, Platzbecker Uwe, Pleyer Lisa, Raj Kavita, Santini Valeria, Sureda Anna, Tobiasson Magnus, Voso Maria Teresa, Yakoub-Agha Ibrahim, Zeidan Amer, Walter Matthew, Kröger Nicolaus, McLornan Donal P, Cazzola Mario
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.
Blood. 2025 May 1;145(18):1987-2001. doi: 10.1182/blood.2024025131.
For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis. Biologic-assignment clinical trials have indicated that in eligible patients, allo-HCT is associated with superior clinical outcomes compared with nontransplant therapy. However, this therapeutic option is only available to a subset of patients, and the outcome is influenced by multiple factors inherent to the patient, the MDS subtype, and the allo-HCT procedure itself. In 2017, the European Society for Blood and Marrow Transplantation (EBMT) published recommendations for allo-HCT in MDS to guide practical decision making. In the contemporary era, genomic profiling has become routine clinical practice in many centers, and the most recent classification systems include MDS entities that are defined by genetic abnormalities. In particular, the molecular International Prognostic Scoring System offers more precise prognostication across all clinical end points and currently represents the standard tool for estimating patient survival in the absence of disease-modifying treatment. Evidence from multiple sources increasingly indicates that allo-HCT should be considered at the time of diagnosis in all eligible patients with MDS. Therefore, genomic profiling for somatic mutations and testing for germ line predisposition variants are integral to determining a patient's eligibility for transplantation. Although all patients with higher-risk MDS are potential candidates for immediate transplantation, a subset of those with lower-risk MDS may also derive benefit from this procedure at an earlier disease stage. Comprehensive recommendations on behalf of an expert international panel for clinical practice and future clinical studies of relevance are presented.
对于骨髓增生异常综合征(MDS)患者而言,异基因造血细胞移植(allo-HCT)是唯一具有潜在治愈可能的治疗方法,能够根除与疾病相关的突变造血细胞并建立正常的供体造血功能。生物学分配临床试验表明,在符合条件的患者中,与非移植治疗相比,allo-HCT具有更好的临床疗效。然而,这种治疗选择仅适用于一部分患者,其结果受到患者自身、MDS亚型以及allo-HCT程序本身等多种内在因素的影响。2017年,欧洲血液和骨髓移植学会(EBMT)发布了MDS患者allo-HCT的推荐意见,以指导实际决策。在当代,基因组分析已成为许多中心的常规临床实践,最新的分类系统包括由基因异常定义的MDS实体。特别是,分子国际预后评分系统在所有临床终点方面提供了更精确的预后评估,目前是在没有疾病修饰治疗的情况下估计患者生存的标准工具。来自多个来源的证据越来越表明,所有符合条件的MDS患者在诊断时都应考虑allo-HCT。因此,体细胞突变的基因组分析和种系易感性变异的检测对于确定患者的移植资格至关重要。虽然所有高危MDS患者都是立即移植的潜在候选人,但一部分低危MDS患者在疾病早期阶段也可能从该程序中获益。本文代表一个国际专家小组提出了关于临床实践和未来相关临床研究的全面建议。